Allergan plc Ordinary Shares (AGN) was Upgraded by Mizuho to ” Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 318 from a previous price target of $248 . Earlier the firm had a rating of “Neutral ” on the company shares. Mizuho advised their investors in a research report released on Aug 19, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Shares were Reiterated by RBC Capital Mkts on Aug 9, 2016 to “Outperform” and Lowered the Price Target to $ 300 from a previous price target of $307 .Shares were Reiterated by Deutsche Bank on Aug 9, 2016 to “Buy” and Lowered the Price Target to $ 278 from a previous price target of $282 .Company shares were Reiterated by Mizuho on Aug 5, 2016 to “Neutral”, Firm has raised the Price Target to $ 246 from a previous price target of $232 .
On the company’s financial health, Allergan plc Ordinary Shares reported $3.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $3.32. The company had revenue of $3709.00 million for the quarter, compared to analysts expectations of $3977.46 million. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.41 EPS.
Allergan plc Ordinary Shares opened for trading at $254 and hit $255.31 on the upside on Wednesday, eventually ending the session at $253.3, with a gain of 0.04% or 0.11 points. The heightened volatility saw the trading volume jump to 34,32,228 shares. Company has a market cap of $100,295 M.
In a different news, on Aug 9, 2016, Nesli Basgoz (director) sold 758 shares at $253.02 per share price. According to the SEC, on Jun 6, 2016, Maria Teresa Hilado (CFO) purchased 661 shares at $241.57 per share price. On Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price, according to the Form-4 filing with the securities and exchange commission.